Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antiangiogenic therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Antiangiogenic therapy. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-008852-18 Sponsor Protocol Number: PRAEMARKERAAT08 Start Date*: 2009-06-10
    Sponsor Name:Medizinische Universität Innsbruck Innere Medizin V
    Full Title: Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients
    Medical condition: The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely wit...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019121-34 Sponsor Protocol Number: E-3810-I-01 Start Date*: 2011-03-28
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics, and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase ...
    Medical condition: Dose escalation: solid tumors failing standard therapy. Dose-expansion: solid tumors A) with FGFR1 amplification and for breast cancer ? 1 prior endocrine therapy if ER+ or ? 1 chemotherapy otherwi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-021590-37 Sponsor Protocol Number: A4061058 Start Date*: 2011-01-03
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017,USA
    Full Title: A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAI...
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001534-11 Sponsor Protocol Number: GIT-PRo-2022-02 Start Date*: 2022-10-11
    Sponsor Name:Grupo Gallego de Investigación en Tumores Digestivos (GITuD)
    Full Title: Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line of treatment.
    Medical condition: Metastatic colorectal cancer (mCRC), stage IV that initiates the first-line systemic treatment in the metastatic setting
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001493-15 Sponsor Protocol Number: UC-0110/1610 Start Date*: 2017-10-13
    Sponsor Name:UNICANCER
    Full Title: A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only col...
    Medical condition: Patients with liver-only non resectable colorectal metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013279-23 Sponsor Protocol Number: NCT-2008-11-02-1020 Start Date*: 2010-03-04
    Sponsor Name:University Hospital of Heidelberg
    Full Title: In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study
    Medical condition: metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009919-21 Sponsor Protocol Number: IDI-ONC-4-20081216 Start Date*: 2009-09-21
    Sponsor Name:ISTITUTO DERMOPATICO IMMACOLATA
    Full Title: Antiangiogenic activity of metronomic therapy with capecitabine in metastatic solid tumors of gastrointestinal tract: a phase II study
    Medical condition: Metastatic solid tumors of gastrointestinal tract
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025680 Malignant miscellaneous gastrointestinal neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002295-18 Sponsor Protocol Number: ML 19033 Start Date*: 2007-01-24
    Sponsor Name:University Hospital, Dept of Oncology, clinical trial unit
    Full Title: ACT: Avastin and Chemotherapy followed by Avastin alone or in combination with Tarceva for the treatment of metastatic colorectal cancer
    Medical condition: Patients with previously untreated metastatic colorectal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013331-37 Sponsor Protocol Number: WSG-AM05 Start Date*: 2011-05-04
    Sponsor Name:WSG GmbH
    Full Title: GALADON - Molecular Imaging Response Assessment of Bevacizumab+Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer
    Medical condition: histologically confirmed locally advanced breast cancer (> cT2); known HER2 status, known ER status
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057654 Breast cancer female LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000559-28 Sponsor Protocol Number: OCTO-062 Start Date*: 2017-01-25
    Sponsor Name:University of Oxford
    Full Title: Randomised phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum–resistant ovarian cancer
    Medical condition: BRCA mutated platinum-resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-004487-53 Sponsor Protocol Number: 2312/2007 Start Date*: 2007-12-13
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Pilot study of association of VEGF polymorphisms with clinical efficacy and tolerability of therapy in patients affected by exudative (neovascular) age-related macular degeneration.
    Medical condition: Exudative and atrophic age-related macular degeneration.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004587-23 Sponsor Protocol Number: UZL/MBC SUBE0501 Start Date*: 2005-12-23
    Sponsor Name:UZ Leuven
    Full Title: A belgian multicenter phase II randomized trial in her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with SU11248 after response to taxane chemotherapy induction
    Medical condition: Patients must meet all of the following inclusion criteria in order to be eligible for participation in this study: • Patients with metastatic breast cancer, histologically proven • Patients receiv...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002326-75 Sponsor Protocol Number: 8-55-58102-004 Start Date*: 2012-09-27
    Sponsor Name:Ipsen Pharma
    Full Title: A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas.
    Medical condition: advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas in patients who have progressed after standard therapies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001230-18 Sponsor Protocol Number: PRO-001 Start Date*: 2019-01-30
    Sponsor Name:Hellenic Genito-Urinary Cancer Group (HGUCG)
    Full Title: Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients. A prospective, randomised, international multicentre, open-label, blinded-endpoint Phase III study. PRO...
    Medical condition: Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000814-65 Sponsor Protocol Number: PACT-12 Start Date*: 2008-02-26
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: Maintenance therapy with Sunitinib in pancreatic adenocarcinoma metastatic: Phase II randomized trial.
    Medical condition: Pancreatic adenocarcinoma metastatic
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001512-65 Sponsor Protocol Number: MEMMATCZ Start Date*: 2012-06-19
    Sponsor Name:Masaryk University
    Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma
    Medical condition: recurrent or progressive medulloblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002115-26 Sponsor Protocol Number: FBH-001 Start Date*: 2019-11-05
    Sponsor Name:Institut Hospitalier Franco-Britanique
    Full Title: Cetuximab as salvage therapy in patients with neo wild-type RAS/RAF metastatic colorectal cancer. A Proof-of-concept study
    Medical condition: colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005770-72 Sponsor Protocol Number: 0681 Start Date*: 2006-01-13
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA MRCC A GOIRC PHASE II STUDY
    Medical condition: Patients with histologically- or cytologically-confirmed, metastatic, clear cell renal cell cancer RCC
    Disease: Version SOC Term Classification Code Term Level
    6.1 10050513 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-002460-33 Sponsor Protocol Number: 005-IRCC-10IIS-14 Start Date*: 2014-10-23
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA - IRCCS
    Full Title: ANTI MEK THERAPY WITH REFAMETINIB TO PREVENT RESISTANCE TO EGFR-TARGETED TREATMENT IN METASTATIC COLORECTAL CANCERS
    Medical condition: metastatic colorectal carcinoma (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10010023 Colorectal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001155-39 Sponsor Protocol Number: D8480C00016 Start Date*: 2012-03-09
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I trial of AZD2171, an orally bioavailable antiangiogenic agent, in children and adolescents with refactory or recurrent solid tumours or acute myelogenous leukemia
    Medical condition: Refractory or recurrent solid tumours or acute myelogenous leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 17:58:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA